Literature DB >> 18351644

Src kinase induces tumor formation in the c-SRC C57BL/6 mouse.

Christina Leah B Kline1, Rosalind Jackson, Robert Engelman, Warren Jack Pledger, Timothy J Yeatman, Rosalyn B Irby.   

Abstract

Src kinase has been linked as a causative agent in the progression of a number of cancers including colon, breast, lung and melanoma. Src protein and activity levels are increased in colorectal cancer and liver metastases arising secondary to colon cancer. However, although Src protein is increased in colon cancer as early as the adenomatous polyp stage, a role for Src in carcinogenesis has not been established. We developed the c-SRC transgenic mouse in the C57BL/6 strain to address the issue of carcinogenesis in cells with high levels of Src expression. The transgene was constructed with the human c-SRC gene downstream of the mouse metallothionein promoter to create zinc inducible gene expression. In these C57BL/6 mice, Src protein was increased in a number of tissues both with and without zinc induction. No additional carcinogenic agent was administered. After 20 months, mice were assessed for tumor development in the liver and GI tract, as well as other organs. Of the mice with the transgene, 15% developed tumors in the liver while no tumors were detected in wild type C57BL/6 mice. A further study was conducted by crossing c-SRC C57BL/6 mice with p21 nullizygous mice to determine the effect of oncogene expression combined with inactivation of the tumor suppressor gene, p21. Addition of the c-SRC transgene to the p21-/- background increased tumor formation almost 3-fold, while it increased metastasis 6-fold. The data from our study show, for the first time, that Src kinase may play a role in carcinogenesis. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18351644     DOI: 10.1002/ijc.23445

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'.

Authors:  Guang Lin; Victoria Aranda; Senthil K Muthuswamy; Nicholas K Tonks
Journal:  Genes Dev       Date:  2011-07-01       Impact factor: 11.361

2.  Oncogenic Ras/Src cooperativity in pancreatic neoplasia.

Authors:  D J Shields; E A Murphy; J S Desgrosellier; A Mielgo; S K M Lau; L A Barnes; J Lesperance; M Huang; C Schmedt; D Tarin; A M Lowy; D A Cheresh
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

3.  Cullin 5 destabilizes Cas to inhibit Src-dependent cell transformation.

Authors:  Anjali Teckchandani; George S Laszlo; Sergi Simó; Khyati Shah; Carissa Pilling; Alexander A Strait; Jonathan A Cooper
Journal:  J Cell Sci       Date:  2013-11-27       Impact factor: 5.285

4.  Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

Authors:  Ralf Buettner; Tania Mesa; Adina Vultur; Frank Lee; Richard Jove
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

5.  Missing-in-Metastasis regulates cell motility and invasion via PTPδ-mediated changes in SRC activity.

Authors:  Fauzia Chaudhary; Robert Lucito; Nicholas K Tonks
Journal:  Biochem J       Date:  2015-01-01       Impact factor: 3.857

6.  Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.

Authors:  A P Algazi; J S Weber; S C Andrews; P Urbas; P N Munster; R C DeConti; J Hwang; V K Sondak; J L Messina; T McCalmont; A I Daud
Journal:  Br J Cancer       Date:  2011-11-29       Impact factor: 7.640

7.  HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expression of Src in liver cells and hepatoma cells.

Authors:  Mingyue Zhu; Junli Guo; Wei Li; Hua Xia; Yan Lu; Xu Dong; Yi Chen; Xieju Xie; Shigan Fu; Mengsen Li
Journal:  BMC Cancer       Date:  2015-05-06       Impact factor: 4.430

8.  Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue.

Authors:  Carole L C Poon; Anthony M Brumby; Helena E Richardson
Journal:  Int J Mol Sci       Date:  2018-05-27       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.